Sturchio, Andrea
Dwivedi, Alok K.
Marsili, Luca
Hadley, Aaron
Sobrero, Gabriele
Heldman, Dustin
Maule, Simona
Lopiano, Leonardo
Comi, Cristoforo
Versino, Maurizio
Espay, Alberto J.
Merola, Aristide http://orcid.org/0000-0002-5587-726X
Funding for this research was provided by:
National Institutes of Health (KL2TR001426)
Article History
Received: 19 July 2020
Revised: 18 September 2020
Accepted: 21 September 2020
First Online: 26 September 2020
Compliance with ethical standards
:
: Dr. Sturchio has no financial conflicts to disclose. Prof. Dwivedi is supported as a co-investigator by the NIH (1 R21 HL143030-01) and (R21 AI133207) grants. He is also currently serving as a statistician in CPRIT-funded studies (PP200006, PP190058, PP180003, and PP170068). Dr. Dwivedi is also an Adjunct Associate Professor in the department of neurology and rehabilitation medicine, University of Cincinnati. Dr. Marsili has no financial conflicts to disclose. Dr. Hadley owns stock in Great Lakes NeuroTechnologies and has received compensation for employment. Dr. Hadley has received grant funding from the NIH. Dr. Sobrero has no financial conflicts to disclose. Dr. Heldman serves on the board of directors of Great Lakes NeuroTechnologies. He also owns stock in Great Lakes NeuroTechnologies and has received compensation for employment. Dr. Maule has no financial conflicts to disclose. Dr. Lopiano has received grant support from Abbvie, Zambon and personal compensation from Abbvie, Zambon, DOC, Bial, UCB. Dr. Comi has received grant support from the “Agenzia Italiana del Farmaco” and from “Fondazione Cariplo”; and travel grants from Zambon S.P.A. and Mylan. Dr. Versino received academic fund support from Chiesi Farmaceutici SpA. Dr. Espay has received grant support from the NIH, Great Lakes Neurotechnologies and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, TEVA, Impax, Acadia, Acorda, Cynapsus/Sunovion, Lundbeck, and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from Abbvie, UCB, USWorldMeds, Lundbeck, Acadia, the American Academy of Neurology, and the Movement Disorders Society. He serves as Associate Editor of the Journal of Clinical Movement Disorders and on the editorial boards of JAMA Neurology, the Journal of Parkinson’s Disease and Parkinsonism and Related Disorders. Dr. Merola is supported by NIH (KL2 TR001426) and has received speaker honoraria from CSL Behring, Abbvie, Abbott, Theravance, and Cynapsus Therapeutics. He has received grant support from Lundbeck and Abbvie.
: The study received IRB/ethics committee approval at all participating centers and was conducted in accordance with the Good Clinical Practice and the International Conference on Harmonization guidelines and any applicable national and local regulations. The authors declare that they acted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
: A. Merola had full access to all the data in the study and takes responsibility for the integrity of the data, the accuracy of the data analysis, and the conduct of the research. He has the right to publish any and all data, separate and apart from the guidance of any sponsor.